Macomics

Macomics is an immuno-oncology company with world-leading expertise in macrophage biology.

Macomics Ltd is an immuno-oncology company with world-leading expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic and has a novel technology platform supporting target discovery and validation. Macomics was co-founded in 2019 by Prof. Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology. It has R&D and office facilities in Edinburgh and Cambridge, UK and is backed by Epidarex Capital, Scottish Enterprise, and Caribou Property Limited.